Advertisement
KROS vs SANA
Which Stock Would AI Choose? Keros Therapeutics (KROS) vs. Sana Biotechnology (SANA) Stock Comparison
Key Takeaways
- KROS is a clinical-stage biopharmaceutical company centered on the TGF-β (transforming growth factor-beta) protein family, while SANA develops engineered cell medicines on its hypoimmune platform.
- Both companies are pre-revenue and unprofitable, making clinical catalysts and cash runway the dominant drivers of relative performance.
- Keros holds a longer cash runway (into the first half of 2028) and a partnered late-stage asset, while Sana carries a shorter runway (mid-2027) after recent equity raises.
- Keros shares have declined sharply year to date, reflecting weak momentum and revenue visibility, whereas Sana's positioning hinges on early human proof-of-concept data in type 1 diabetes.
- The two stocks represent contrasting risk profiles: a more de-risked, execution-focused story versus a higher-risk, higher-reward platform narrative.
Introduction
Keros Therapeutics and Sana Biotechnology are two development-stage biotech companies that sit at different points on the clinical risk spectrum. Both depend on advancing unproven therapies rather than generating product sales, which makes their comparison useful for investors who follow clinical catalysts, financing runway, and relative momentum. Keros is narrowing its focus around a lead muscle-disease program while leaning on a large pharmaceutical partnership. Sana is pursuing a platform-based approach to cell therapy with several early-stage programs. This stock comparison examines business models, recent market behavior, and market positioning to help traders and investors weigh these two names in the current environment.
KROS Overview and Recent Performance
Keros Therapeutics is a clinical-stage biopharmaceutical company that develops protein therapeutics targeting the TGF-β family of proteins, which regulate the growth and repair of tissues including muscle, bone, and blood. Its lead wholly owned candidate, rinvatercept, is being developed for Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS), while its most advanced asset, elritercept, is partnered with Takeda for blood disorders such as myelodysplastic syndromes (MDS) and myelofibrosis.
Recent market activity has been challenging for Keros. The stock has declined substantially year to date, reflecting weak momentum and limited revenue visibility, since the company has no marketed products and reported essentially no revenue in the first half of 2026. The Takeda collaboration provides milestone and royalty upside, but quarterly results remain lumpy. A brighter spot is the balance sheet: Keros reported cash and cash equivalents of roughly $257.6 million as of June 30, 2026, with management expecting that runway to fund operations into the first half of 2028. The company has initiated a Phase 2 DMD trial of rinvatercept, with initial data anticipated in the first half of 2027.
SANA Overview and Recent Performance
Sana Biotechnology is a biotechnology company focused on engineered cells as medicines, built around its hypoimmune (HIP) platform, which is designed to allow transplanted cells to evade the immune system without immunosuppression. Its pipeline includes SC451, a stem-cell-derived pancreatic islet cell therapy for type 1 diabetes, and SG293, an in vivo CAR T (chimeric antigen receptor T-cell) program for B-cell diseases, along with the investigator-sponsored UP421 islet cell program.
Sana's recent stock behavior has been volatile and tied closely to early data and financing activity. A New England Journal of Medicine publication described a type 1 diabetes patient producing C-peptide after UP421 transplantation without immunosuppression, a notable early validation of the platform. In recent months, the company strengthened its balance sheet through an at-the-market (ATM) offering of roughly $69 million plus a separate Mayo Clinic investment, extending its cash runway to mid-2027. Sana reported cash, cash equivalents, and marketable securities of about $160.5 million as of June 30, 2026, and continues to expect an IND (Investigational New Drug) filing for SC451, with the program positioned as a central near-term catalyst.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's best-performing AI trading bots, chosen for their suitability to current market conditions. Tickeron offers hundreds of AI Trading Bots that monitor thousands of tickers, yet only those demonstrating the strongest alignment with today's market environment earn a place in this section. These bots differ widely in trading style, strategy, timeframe, performance statistics, and the set of tickers they trade, ranging from short-term intraday approaches to longer-horizon swing and trend strategies. For traders comparing names such as KROS and SANA, exploring these quantitative, rules-based systems can add a data-driven layer to a fundamentally focused analysis. Visit the Trending AI Robots page to review the current lineup.
Head-to-Head Comparison
The two companies diverge most clearly in business model and risk profile. Keros pursues a focused, protein-therapeutics strategy with a single lead asset and a partnered late-stage program, which shifts development costs to Takeda while preserving milestone and royalty upside. Sana runs a broader platform spanning multiple programs and therapeutic areas, offering potentially larger optionality but also greater technical and regulatory uncertainty.
On growth drivers, Keros is anchored by the rinvatercept DMD readout expected in the first half of 2027 and by Takeda-led elritercept trials. Sana's momentum rests on SC451's IND filing and subsequent human data, alongside SG293's early development. Financially, Keros holds the stronger near-term position, with a longer runway and a non-dilutive partner income stream, whereas Sana has already relied on equity sales and carries a shorter runway to mid-2027.
From a sentiment standpoint, Keros has faced a sustained decline in share price and weak momentum scores, while Sana's narrative has been shaped by high-profile early data and subsequent capital raises. Sector exposure is comparable in that both sit in clinical-stage biotechnology, but Keros competes in a neuromuscular field with established players, while Sana operates in the less crowded, though unproven, allogeneic cell therapy arena.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor Keros Therapeutics over Sana Biotechnology at present, with a probabilistic rather than definitive view. Keros offers a longer cash runway into the first half of 2028, a partnered late-stage asset that reduces development spending while retaining milestone upside, and a defined near-term catalyst in the rinvatercept DMD data. Sana presents a more speculative profile, with a shorter runway and dependence on early-stage proof-of-concept data. While Keros's weak recent momentum warrants caution, its combination of balance-sheet stability and clearer execution milestones gives it a modest relative edge in this comparison, consistent with the principles of trend consistency and catalyst positioning.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KROS is a StrongBuy and SANA is a Hold.
KROS's Stochastic Oscillator is sitting in oversold zone for 3 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on KROS as a result. In 77 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
KROS moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +6.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where KROS advanced for three days, in 227 of 296 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
KROS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 193 of 227 cases where KROS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for KROS turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 30 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KROS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.862) is normal, around the industry mean (3.009). P/E Ratio (-3.540) is within average values for comparable stocks, (-1.027). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.622) among similar stocks. P/S Ratio (19.417) is also within normal values, averaging (438.009).
The Tickeron Seasonality Score of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. KROS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KROS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
SANA's Indicator enters downward trend
The Aroon Indicator for SANA entered a downward trend on October 20, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 311 similar instances where the Aroon Indicator formed such a pattern. In 275 of the 311 cases the stock moved lower. This puts the odds of a downward move at 88%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SANA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SANA's RSI Oscillator exited the oversold zone, 36 of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 17 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where SANA advanced for three days, in 190 of 240 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
SANA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.571) is normal, around the industry mean (3.009). P/E Ratio (-3.147) is within average values for comparable stocks, (-1.027). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.622) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. SANA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SANA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
KROS | ||
|---|---|---|
OUTLOOK RATING 1..100 | 24 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 26 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 95 | |
PRICE GROWTH RATING 1..100 | 56 | |
P/E GROWTH RATING 1..100 | 97 | |
SEASONALITY SCORE 1..100 | 48 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| KROS | SANA | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 85% | 1 day ago 88% |
| Momentum ODDS (%) | 1 day ago 83% | N/A |
| MACD ODDS (%) | 1 day ago 71% | N/A |
| TrendWeek ODDS (%) | 1 day ago 77% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 79% | 1 day ago 89% |
| Advances ODDS (%) | 1 day ago 77% | 1 day ago 79% |
| Declines ODDS (%) | 7 days ago 74% | 7 days ago 88% |
| BollingerBands ODDS (%) | 1 day ago 80% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 85% | 1 day ago 88% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
KROS’s FA Score shows that 1 FA rating(s) are green while SANA’s FA Score has 1 green FA rating(s).
- KROS’s FA Score: 1 green, 4 red.
- SANA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
KROS’s TA Score shows that 6 TA indicator(s) are bullish while SANA’s TA Score has 4 bullish TA indicator(s).
- KROS’s TA Score: 6 bullish, 2 bearish.
- SANA’s TA Score: 4 bullish, 2 bearish.
Price Growth
KROS (@Biotechnology) experienced а +1.51% price change this week, while SANA (@Biotechnology) price change was -2.07% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.45%. For the same industry, the average monthly price growth was -16.03%, and the average quarterly price growth was -14.84%.
Reported Earning Dates
KROS is expected to report earnings on Nov 04, 2026.
SANA is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Biotechnology (-0.45% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
KROS and
Correlation & Price change
A.I.dvisor indicates that over the last year, KROS has been loosely correlated with SANA. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if KROS jumps, then SANA could also see price increases.
| Ticker / NAME | Correlation To KROS | 1D Price Change % | ||
|---|---|---|---|---|
| KROS | 100% | +3.07% | ||
| SANA - KROS | 49% Loosely correlated | +2.61% | ||
| AXON - KROS | 43% Loosely correlated | +2.49% | ||
| IMVT - KROS | 43% Loosely correlated | +3.51% | ||
| ABEO - KROS | 43% Loosely correlated | +4.31% | ||
| EYPT - KROS | 43% Loosely correlated | -7.91% | ||
More | ||||
SANA and
Correlation & Price change
A.I.dvisor indicates that over the last year, SANA has been loosely correlated with EDIT. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if SANA jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To SANA | 1D Price Change % | ||
|---|---|---|---|---|
| SANA | 100% | +2.61% | ||
| EDIT - SANA | 58% Loosely correlated | +6.61% | ||
| RCKT - SANA | 57% Loosely correlated | +4.46% | ||
| BEAM - SANA | 56% Loosely correlated | +3.06% | ||
| CRSP - SANA | 56% Loosely correlated | -0.32% | ||
| ABSI - SANA | 54% Loosely correlated | +6.21% | ||
More | ||||